ASCO GU 2025 Kidney Cancer

Viewing 1-20 of 30 articles

ASCO GU 2025: Case-Based Session: Failure of Immunotherapy in Renal Cell Cancer – What’s Next

ASCO GU 2025: The Future of Biomarkers in Renal Cell Carcinoma

ASCO GU 2025: Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point?

ASCO GU 2025: Adjuvant Therapy in Renal Cell Cancer: A Practical Guide

ASCO GU 2025: Evaluation of Circulating Kidney Injury Marker-1 (KIM-1) as a Prognostic and Predictive Biomarker in Advanced Renal Cell Carcinoma: Post-Hoc Analysis of CheckMate 214

ASCO GU 2025: Final Overall Survival and New ctDNA Analysis in MET-Driven Advanced Papillary Renal Cancer (CALYPSO)

ASCO GU 2025: Nivolumab plus Cabozantinib vs Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma: Final Follow-up Results from the CheckMate 9ER Trial

ASCO GU 2025: Casdatifan Monotherapy in Patients with Previously Treated Clear Cell Renal Cell Carcinoma (ccRCC): Safety, Efficacy and Subgroup Analysis Across Multiple Doses from ARC-20, a Phase 1 Open-Label Study

ASCO GU 2025: Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR)

ASCO GU 2025: KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ASCO GU 2025: Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191)

ASCO GU 2025: Lenvatinib plus Tislelizumab as First-Line Therapy for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Single-Center, Single-Arm, Phase II Study

ASCO GU 2025: Cabozantinib in Combination with Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma (aRCC): Final Results of COSMIC-313

ASCO GU 2025: A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

ASCO GU 2025: Real-World Analysis of Pembrolizumab Utilization and Characteristics of Patients Being Prescribed Treatment in Early Stage RCC

ASCO GU 2025: Updated Results of the TIDE-A Study Evaluating Avelumab plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma (mRCC).

ASCO GU 2025: Updated Results From the Phase 2 LITESPARK-003 Study of Belzutifan Plus Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.

ASCO GU 2025: 18F-PSMA-1007 PET/CT for Response Assessment in Patients with mRCC Undergoing First Line Tyrosine Kinase or Checkpoint Inhibitor Therapy

ASCO GU 2025: State of the Genitourinary Medical Oncology Workforce in the United States, 2024

1
2